SKF83959

SKF83959 is a synthetic small molecule belonging to the benzazepine class, primarily studied as a **partial agonist at dopamine D1-like receptors** (notably D1 and D5), and as an **allosteric modulator of the sigma-1 receptor**. It was originally developed by SmithKline Beecham. Unlike classical D1 agonists, SKF83959 shows biased activity toward G protein-mediated pathways; its selectivity and in vivo effects have made it a tool compound in neuropharmacology, especially in research on **Parkinson's disease** and **depression**. It also acts as a **triple monoamine reuptake inhibitor**, inhibiting serotonin (SERT), norepinephrine (NET), and dopamine (DAT) transporters, which is believed to account for its antidepressant effects in preclinical models. Neuroprotective and anti-neuroinflammatory actions have been observed, with efficacy signals in models of memory impairment and depressive-like behavior. SKF83959 has no approved medical use in humans and is utilized solely in research contexts[1][3][5][7][9][10].

Other names

6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepineSKF83959 hydrobromideSKF-83959 hydrobromideSKF 83959 hydrobromide